| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.77 [0.70, 0.85] | | < 1 | | 32% | 9 studies (9/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.53 [0.22, 1.23] | | < 1 | | 77% | 2 studies (2/-) | 93.0 % | some concern | not evaluable | moderate | important | - |
| PFS (extension) | 0.69 [0.44, 1.07] | | < 1 | | 46% | 2 studies (2/-) | 95.2 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.90 [0.79, 1.01] | | < 1 | | 60% | 9 studies (9/-) | 96.1 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.70 [1.26, 2.31] | | > 1 | | 59% | 9 studies (9/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) (extension) | 1.63 [0.19, 14.17] | | > 1 | | 91% | 2 studies (2/-) | 67.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.65 [0.41, 1.02] | | < 1 | | 0% | 5 studies (5/-) | 96.8 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.51 [0.36, 0.72] | | < 1 | | 61% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 0.97 [0.52, 1.80] | | < 1 | | 0% | 4 studies (4/-) | 53.9 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.51 [0.33, 0.76] | | < 1 | | 35% | 3 studies (3/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.24 [0.83, 1.86] | | < 1 | | 0% | 3 studies (3/-) | 14.8 % | some concern | not evaluable | moderate | non important | - |
| SAE (grade 3-4) | 0.34 [0.03, 3.42] | | < 1 | | 93% | 2 studies (2/-) | 81.8 % | some concern | not evaluable | moderate | non important | - |
| STRAE (any grade) | 0.40 [0.29, 0.57] | | < 1 | | 30% | 6 studies (6/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.29 [0.19, 0.45] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.29 [0.24, 0.37] | | < 1 | | 24% | 7 studies (7/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.15 [0.10, 0.21] | | < 1 | | 73% | 8 studies (8/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.32 [0.14, 0.71] | | < 1 | | 0% | 6 studies (6/-) | 99.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.40 [0.21, 0.77] | | < 1 | | 58% | 5 studies (5/-) | 99.7 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.52 [0.16, 1.64] | | < 1 | | 44% | 2 studies (2/-) | 86.8 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.49 [0.02, 14.75] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.01 [0.15, 6.65] | | < 1 | | 0% | 4 studies (4/-) | 49.7 % | some concern | not evaluable | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.95 [0.18, 21.69] | | < 1 | | 0% | 2 studies (2/-) | 29.5 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.65 [0.10, 4.29] | | < 1 | | 0% | 4 studies (4/-) | 67.2 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.10 [0.03, 0.30] | | < 1 | | 0% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.72 [0.08, 6.15] | | < 1 | | 0% | 3 studies (3/-) | 61.9 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.11 [0.03, 0.37] | | < 1 | | 0% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 1.81 [0.33, 10.03] | | < 1 | | 0% | 4 studies (4/-) | 24.9 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.44 [0.06, 3.16] | | < 1 | | 0% | 3 studies (3/-) | 79.3 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.28 [0.07, 1.14] | | < 1 | | 0% | 5 studies (5/-) | 96.2 % | some concern | not evaluable | moderate | non important | - |
| Dermatitis acneiform TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.41 [0.12, 1.38] | | < 1 | | 0% | 5 studies (5/-) | 92.4 % | some concern | not evaluable | moderate | non important | - |
| Dizziness TRAE (grade 3-4) | 0.98 [0.02, 50.00] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.46 [0.04, 5.13] | | < 1 | | 0% | 1 study (1/-) | 73.3 % | NA | not evaluable | | non important | - |
| Eczema TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.46 [0.01, 23.40] | | < 1 | | 0% | 1 study (1/-) | 64.7 % | NA | not evaluable | | non important | - |
| Erythema TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.19 [0.09, 0.41] | | < 1 | | 0% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.03 [0.01, 0.11] | | < 1 | | 0% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 0.93 [0.03, 27.74] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.46 [0.02, 13.86] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.39 [0.14, 13.49] | | < 1 | | 0% | 1 study (1/-) | 38.8 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.44 [0.06, 3.38] | | < 1 | | 0% | 3 studies (3/-) | 78.6 % | some concern | not evaluable | moderate | non important | - |
| Hypertension TRAE (grade 3-4) | 1.86 [0.17, 20.62] | | < 1 | | 0% | 1 study (1/-) | 30.8 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.76 [0.08, 7.33] | | < 1 | | 0% | 3 studies (3/-) | 59.3 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.00 [0.15, 6.60] | | < 1 | | 0% | 4 studies (4/-) | 50.0 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 0.81 [0.09, 6.95] | | < 1 | | 0% | 2 studies (2/-) | 57.6 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.91 [0.16, 5.34] | | < 1 | | 0% | 3 studies (3/-) | 54.1 % | some concern | not evaluable | moderate | non important | - |
| Increased lacrimation (TRAE grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 3.14 [0.49, 19.89] | | < 1 | | 0% | 2 studies (2/-) | 11.3 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.85 [0.41, 8.37] | | < 1 | | 0% | 4 studies (4/-) | 21.3 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.06 [0.02, 0.17] | | < 1 | | 0% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.17 [0.03, 1.05] | | < 1 | | 0% | 3 studies (3/-) | 97.1 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 0.55 [0.08, 3.90] | | < 1 | | 0% | 3 studies (3/-) | 72.3 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 0.93 [0.02, 46.93] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.41 [0.11, 1.53] | | < 1 | | 0% | 4 studies (4/-) | 90.8 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.02 [0.01, 0.06] | | < 1 | | 0% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.63 [0.05, 8.17] | | < 1 | | 0% | 2 studies (2/-) | 63.9 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.96 [0.06, 15.39] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.16 [0.03, 0.88] | | < 1 | | 0% | 3 studies (3/-) | 98.2 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 0.35 [0.05, 2.46] | | < 1 | | 0% | 3 studies (3/-) | 85.3 % | some concern | not evaluable | moderate | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 0.46 [0.02, 13.86] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.32 [0.03, 3.34] | | < 1 | | 27% | 2 studies (2/-) | 82.9 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.55 [0.74, 8.78] | | < 1 | | 0% | 5 studies (5/-) | 6.9 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Pruritus generalised TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.72 [0.08, 6.19] | | < 1 | | 0% | 3 studies (3/-) | 61.7 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.06 [0.23, 4.87] | | < 1 | | 0% | 4 studies (4/-) | 47.1 % | some concern | not evaluable | moderate | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 0.46 [0.01, 23.40] | | < 1 | | 0% | 1 study (1/-) | 64.7 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 6.60 [0.37, 116.99] | | < 1 | | 0% | 1 study (1/-) | 10.2 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.23 [0.01, 5.14] | | < 1 | | 0% | 1 study (1/-) | 82.0 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 2.79 [0.14, 56.11] | | < 1 | | 0% | 1 study (1/-) | 25.4 % | NA | not evaluable | | non important | - |
| Skin exfoliation TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.37 [0.06, 2.30] | | < 1 | | 0% | 3 studies (3/-) | 85.6 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.66 [0.04, 10.53] | | < 1 | | 0% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| Urticaria TRAE (grade 3-4) | 0.93 [0.02, 47.22] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.46 [0.01, 23.40] | | < 1 | | 0% | 1 study (1/-) | 64.7 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.35 [0.05, 2.48] | | < 1 | | 0% | 3 studies (3/-) | 85.2 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.93 [0.06, 14.90] | | < 1 | | 0% | 1 study (1/-) | 52.1 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
